Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 866-870

  Khalaf, Daniel ^a,b   Hilton, John F ^b   Clemons, Mark ^b   Azoulay, Laurent ^c,d   Yin, Hui ^d   Vandermeer, Lisa ^b   Dent, Susan ^b   Hopkins, Sean ^b   Bouganim, Nathaniel ^c  

^a NOTRE DAME HOSPITAL   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Metastatic breast cancer; Platinum; Time to progression; Triple negative breast cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MIDDLE AGED; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST CANCER;

EID: 84892971685     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1782     Document Type: Article

References (19)

1. Clemons M, Leahy M, Valle J, et al: Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. Eur J Cancer 33: 2171-2182, 1997.
2. Tassone P, Tagliaferri P, Perricelli A, et al: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88: 1285-1291, 2003.
3. Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med 363: 1938-1948, 2010.
4. Santana-Davila R and Perez EA: Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 3: 42, 2010.
5. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol28: 375-379, 2010.
6. Staudacher L, Cottu PH, Dieras V, et al: Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 22: 848-856, 2011.
7. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol28: 1145-1153, 2010.
8. Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II study (Bali-1). In: Abstract Book of the 35th ESMO congress; 2010 Oct 8-12; Milan, Italy. Annals of Oncology. 21: viii1-viii96.
9. Isakoff SJ: Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 16: 53-61, 2010.
10. Kassam F, Enright K, Dent R, et al: Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer9: 29-33, 2009.
11. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol28: 2784-2795, 2010.
12. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
13. O'Shaughnessy J, Osborne C, Pippen JE, et al: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364: 205-214, 2011.
14. Carey LA, Rugo HS, Marcom PK, etal: TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol26 (Suppl15): 1009, 2008.
15. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.
16. Robert NJ, Dieras V, Glaspy J, et al: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29: 1252-1260, 2011.
17. Sledge GW Jr, Loehrer PJ Sr, Roth BJ and Einhorn LH: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6: 1811-1814, 1988.
18. Kolarić K and Roth A: Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11: 108-112, 1983.
19. Perez EA: Carboplatin in combination therapy for metastatic breast cancer. Oncologist 9: 518-527, 2004.